UPDATE: GPhA welcomes FTC move on biogenerics

Responding to the recent US Federal Trade Commission's roundtable on Emerging Health Care Competition and Consumer Issues, which addressed the contentious subject of follow-on biologic drugs, the Generic Pharmaceutical Association's chief executive, Kathleen Jaeger, said: "the mere fact that the FTC is conducting this roundtable demonstrates the growing momentum behind ensuring that consumers have access to safe and affordable biogenerics sooner rather than later."

New Admin focus likely